Health ❯ Healthcare ❯ Cardiology

Heart Disease

Heart Attack Cholesterol Management Heart Failure Risk Factors LDL Cholesterol Inflammation Treatment Options Treatment Mortality Rates Risk Assessment

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Phase 3 trials showed roughly 56–59% reductions in LDL cholesterol and the pill will carry a $315 monthly list price.

Dapagliflozin Cuts Heart-Failure Hospitalizations by About 80% in People With Cardiomyopathy Genes

Single Infusion Gene Editing Lowers LDL by Up to 62% in Early Trial

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

One in Three NHS Heart Ultrasounds Found Non-Diagnostic, UEA Study Says

Oxford AI Flags Heart Failure Risk Up to Five Years Early on CT Scans

Early High Blood Pressure Tied to Higher Midlife Heart and Kidney Risks

New U.S. Cholesterol Guideline Shifts Prevention Earlier, Endorses PREVENT and Clear LDL Goals

Japan Panel Clears iPS Cell Therapies for Heart Failure and Parkinson’s

Heart Attack Alerts Shift Toward Younger Adults as German Experts Push Prevention

Vast Study Finds 99% of First Heart Attacks, Strokes Tied to Prior Risk Factors

University of Michigan AI Detects Microvascular Heart Disease From a 10-Second EKG

Abdominal Fat, Not BMI, Linked to Harmful Heart Remodeling in MRI Study

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

Personalized Vitamin D Strategy Halves Risk of Repeat Heart Attack in Randomized Trial

Oral PCSK9 Pill Enlicitide Cuts LDL Up to 60% in Phase 3 Trial

Three-Biomarker Panel Flags Nearly Triple Heart Attack Risk in AHA 2025 Study

Large Wearable Study Ties Nighttime Light to Higher Heart Disease Risk

Mayo Study Finds Many Heart Attacks in Younger Women Aren’t Caused by Artery Blockages

ACC Issues Scientific Statement on Inflammation in Heart Disease, Endorsing hsCRP for Risk Assessment